Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2270 PWToday Stories

Cardax and GNC Sign Mutual Exclusivity Agreement for ZanthoSyn®

20 Oct 17

Cardax, Inc. (OTCQB:CDXI) announced today that it has entered into a mutual exclusivity agreement with General Nutrition Corporation ("GNC") for ZanthoSyn, the Company's premium astaxanthin dietary supplement for inflammatory health and longevity.*

The exclusivity agreement builds on the Company's recently announced national rollout of ZanthoSyn across GNC's more than 3,200 US corporate stores and now designates GNC as the exclusive "brick-and-mortar" retailer of ZanthoSyn in the United States. ZanthoSyn will also continue to be available online at,, and

The exclusivity agreement covers the use of ZanthoSyn as a human dietary supplement, with an initial term of two years and provides for automatic renewals.

The exclusivity obligation is subject to GNC continuing to stock ZanthoSyn across all of its US corporate stores and GNC not selling a competing house-branded astaxanthin dietary supplement (synthetic or natural) or a competing synthetic astaxanthin dietary supplement from other vendors.

"We are delighted with this mutual exclusivity agreement," said David G. Watumull, Cardax CEO. "Our growing relationship with GNC builds on the exceptional sales of ZanthoSyn in Hawaii GNC stores and will leverage GNC's more than 10,000 person in-store sales force to actively market ZanthoSyn across the US."

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.